Esperion Therapeutics (ESPR) EBIT (2018 - 2025)
Historic EBIT for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$10.0 million.
- Esperion Therapeutics' EBIT rose 3785.72% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 27854.76%. This contributed to the annual value of $54.4 million for FY2024, which is 13497.1% up from last year.
- Per Esperion Therapeutics' latest filing, its EBIT stood at -$10.0 million for Q3 2025, which was up 3785.72% from $7.1 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' EBIT registered a high of $72.3 million during Q1 2024, and its lowest value of -$82.8 million during Q1 2021.
- Over the past 5 years, Esperion Therapeutics' median EBIT value was -$37.1 million (recorded in 2023), while the average stood at -$28.0 million.
- Its EBIT has fluctuated over the past 5 years, first surged by 24868.63% in 2024, then crashed by 13057.47% in 2025.
- Esperion Therapeutics' EBIT (Quarter) stood at -$55.6 million in 2021, then rose by 23.58% to -$42.5 million in 2022, then increased by 0.34% to -$42.4 million in 2023, then skyrocketed by 89.57% to -$4.4 million in 2024, then plummeted by 125.32% to -$10.0 million in 2025.
- Its last three reported values are -$10.0 million in Q3 2025, $7.1 million for Q2 2025, and -$22.1 million during Q1 2025.